Original Research Article
Patterns of Cortical Thickness according to APOE Genotype in Alzheimer’s DiseaseGutiérrez-Galve L.a, c, d · Lehmann M.a · Hobbs N.Z.a · Clarkson M.J.a, b · Ridgway G.R.a, b · Crutch S.a · Ourselin S.a, b · Schott J.M.a · Fox N.C.a · Barnes J.a
aDementia Research Centre, Institute of Neurology, and bCentre for Medical Image Computing (CMIC), University College London (UCL), London, UK; cCentro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spanish Ministry of Health, Madrid, and dInstituto Aragonés de Ciencias de la Salud, Zaragoza, Spain
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background: Possession of one or more apolipoprotein E (APOE) ε4 alleles may influence the distribution of atrophy and clinical phenotype. We aimed to assess the influence of APOE genotype on cortical thickness and regional brain volumes in AD (Alzheimer’s disease). Methods: We included 38 patients (9 ε4 non-carriers, 23 ε4 heterozygotes, 6 ε4 homozygotes) and 23 controls. Each subject had 2 magnetic resonance imaging (MRI) scans and a neuropsychological battery. Cortical thickness and isthmus cingulate volume were measured using FreeSurfer; the volumes of the hippocampus, whole brain, and lateral ventricles were calculated using manual and semi-automated volumetry. Results: Compared with controls, cortical thickness was significantly lower: in the bilateral temporal, posterior parietal and occipital regions in non-carriers, in the medial temporal and left parietal regions in heterozygotes, and in the medial temporal lobe in homozygotes. Comparisons between AD subgroups did not show significant differences. A trend for larger brain and isthmus cingulate volumes and smaller hippocampal and ventricular volumes with increasing ε4 dose were seen. These differences were supported by neuropsychological profiles. Conclusion: These results suggest that APOE genotype may influence the topography of regional atrophy and cortical thinning in AD.
© 2009 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.